- Home
- NMM vs NVCR Comparison
NMM vs NVCR Comparison
Compare NMM & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- NVCR
- Stock Information
- Founded
- NMM 2007
- NVCR 2000
- Country
- NMM Greece
- NVCR Switzerland
- Employees
- NMM N/A
- NVCR N/A
- Industry
- NMM Marine Transportation
- NVCR Medical/Dental Instruments
- Sector
- NMM Consumer Discretionary
- NVCR Health Care
- Exchange
- NMM Nasdaq
- NVCR Nasdaq
- Market Cap
- NMM 1.3B
- NVCR 1.3B
- IPO Year
- NMM 2007
- NVCR 2015
- Fundamental
- Price
- NMM $52.93
- NVCR $12.18
- Analyst Decision
- NMM
- NVCR Buy
- Analyst Count
- NMM 0
- NVCR 7
- Target Price
- NMM N/A
- NVCR $28.64
- AVG Volume (30 Days)
- NMM 115.9K
- NVCR 1.7M
- Earning Date
- NMM 11-18-2025
- NVCR 10-30-2025
- Dividend Yield
- NMM 0.38%
- NVCR N/A
- EPS Growth
- NMM N/A
- NVCR N/A
- EPS
- NMM 8.94
- NVCR N/A
- Revenue
- NMM $1,311,114,000.00
- NVCR $642,269,000.00
- Revenue This Year
- NMM N/A
- NVCR $9.54
- Revenue Next Year
- NMM $9.93
- NVCR $5.70
- P/E Ratio
- NMM $5.85
- NVCR N/A
- Revenue Growth
- NMM N/A
- NVCR 11.17
- 52 Week Low
- NMM $28.37
- NVCR $10.70
- 52 Week High
- NMM $54.52
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- NMM 68.27
- NVCR 49.90
- Support Level
- NMM $52.04
- NVCR $11.38
- Resistance Level
- NMM $54.12
- NVCR $11.63
- Average True Range (ATR)
- NMM 1.51
- NVCR 0.52
- MACD
- NMM 0.10
- NVCR 0.09
- Stochastic Oscillator
- NMM 69.00
- NVCR 94.81
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.